Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2019
Reporting Period: Single event date (August 14, 2019)
Business Context: The Company is an emerging growth company incorporated in Nevada, trading on NASDAQ. This filing serves as a Regulation FD disclosure regarding the publication of an Investor Fact Sheet on the Company's website.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate communication event rather than a financial statement.
Material Changes
No material financial changes or operational results are reported in this filing. The material event is the release of an Investor Fact Sheet containing updates on the product pipeline, clinical trials, and leadership information.
Guidance, Outlook, and Risks
Management Commentary: The Company published a Fact Sheet (Exhibit 99.1) detailing updates to its product pipeline and clinical trials. The filing explicitly states that the Fact Sheet is furnished but not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K report.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Fact Sheet) for specific details on pipeline and clinical trial updates, as the 8-K body only references the document.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm that the Fact Sheet is not legally incorporated into other SEC filings, limiting liability under Section 18 of the Exchange Act.
- Check subsequent filings (e.g., 10-Q or 10-K) for the actual financial metrics absent from this report.